Showing results (1-10 of 185) with videos related to
Sort By:
Pageof 19
Expert Review of Clinical Pharmacology|May 22, 2016
Three-month paliperidone palmitate - a new treatment option for schizophreniaMiquel Bernardo, Miquel BioqueExpert Opinion on Pharmacotherapy|September 25, 2018
The current data on the 3-month paliperidone palmitate formulation for the treatment of schizophreniaMiquel Bioque, Miquel BernardoActas Espanolas De Psiquiatria|July 25, 2023
CONSENSUS BY THE COLLECTIVE OF PSYCHIATRISTS FOR THE CLOZAPINE UPDATEMiquel Bernardo, Emilio Fernández-EgeaEuropean Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|May 23, 2012
Functional analysis of gene expression in risperidone treated cells provide new insights in molecular mechanism and new candidate genes for pharmacogenetic studiesSergi Mas, Patricia Gassó, Miquel Bernardo, et al.International Journal of Psychiatry in Clinical Practice|June 27, 2012
Factors associated with relapse in patients with schizophreniaLuis San, Miquel Bernardo, Agustín Gómez, et al.Revista De Psiquiatria Y Salud Mental|August 3, 2012
[Clozapine and agranulocitosis in Spain: do we have a safer population? A 5-year hematologic follow-up]Alexander Pons, Juan Undurraga, Albert Batalla, et al.Therapeutic Advances in Psychopharmacology|October 18, 2024
Risperidone ISM®: review and update of its usefulness in all phases of schizophreniaThomas Messer, Miquel Bernardo, Lourdes Anta, et al.Pharmacogenomics|November 23, 2012
Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs studySergi Mas, Adrián Llerena, Jerónimo Saíz, et al.Fundamental & Clinical Pharmacology|September 20, 2011
Sulforaphane protects SK-N-SH cells against antipsychotic-induced oxidative stressSergi Mas, Patricia Gassó, Gemma Trias, et al.Expert Review of Neurotherapeutics|June 15, 2007
Oxcarbazepine in the treatment of bipolar and schizoaffective disordersEkaterine Popova, Caroline Leighton, Antoni Bernabarre, et al.Pageof 19